Ou HY, et al. - In this study, researchers analyzed 549 subjects to assess the effect of Helicobacter pylori infection status and its eradication on glycemic control and antidiabetic therapy in patients with type 2 diabetes. They recorded more prescriptions of oral antidiabetic drug classes and a greater percentage of sulfonylurea use (67.3% vs 50.4%) vs the "non-active" infection group with no between-group difference in hemoglobin A1c (A1C). No variations were reported in A1C and oral antidiabetic drug classes between "past" and "never/remote" infection groups. They found significant within-group (−0.17 ± 0.80%) and between-group (−0.23 ± 0.10%) improvements in A1C in the eradication group vs the non-eradication group. Overall, findings suggested the requirement of higher glycemic treatment intensity in diabetic candidates with active H. pylori infection to achieve comparable glycemia.